Differential Urinary Proteomic Analysis of Endometrial Cancer

M. KACÍROVÁ1, P. BOBER1, M. ALEXOVIČ1, Z. TOMKOVÁ1, S. TKÁČIKOVÁ1, I. TALIAN1, L. MEDEROVÁ2, D. BÉREŠOVÁ2, R. TÓTH2, I. ANDRAŠINA2, Z. KOŽLEJOVÁ3, R. KILIK4, R. DIVÍN5,6, J. SABO1,6,7

1Department of Medical and Clinical Biophysics, Faculty of Medicine, Pavol Jozef Šafárik University, Košice, Slovakia, 2Department of Radiotherapy and Oncology, Faculty of Medicine, Pavol Jozef Šafárik University, East Slovakia Oncology Institute, Košice, Slovakia, 3Slovakin, Faculty of Medicine, Pavol Jozef Šafárik University, Košice, Slovakia, 4First Department of Surgery, Faculty of Medicine, Pavol Jozef Šafárik University, Košice, Slovakia, 5Faculty of Biomedical Engineering, Czech Technical University in Prague, Kladno, Czech Republic, 6Department of Biophysics, Second Faculty of Medicine, Charles University, Prague, Czech Republic, 7Czech Technical University in Prague, University Center for Energy Efficient Buildings, Buštěhrad, Czech Republic

Received August 16, 2019
Accepted September 25, 2019

Summary
Endometrial cancer is one of the most frequent gynecological malignancies present in more than 95% of all uterine cancers. In spite of that, screening of such disease is not commonly performed in clinical practice due to enormous costs and relatively low sensitivity. Therefore, developing an effective screening test to diagnose endometrial cancer at early stages is of great importance for the clinical area of investigation. In this work, we applied urinary proteomics (i.e., bottom-up proteomic approach followed by nano HPLC-ESI-MS/MS) in patients with endometrial cancer, with respect to find proteins aimed for the early diagnostics and screening. According to the results, the significant semi-quantitative changes were observed in urinary proteome of treated patients. The proteins that may be pivotal in pathogenesis of endometrial cancer, like cadherin-1 (CDH1), vitronectin (VTN) and basement membrane specific-heparan sulphate proteoglycan core protein (HSPG2) were down-regulated, when compared to the control group. Ultimately, it can be stated that urinary proteomics has a potential for the searching of cancer protein biomarkers based on their altered concentration.

Key words
Endometrial cancer • Proteomics • Urine • Biomarkers

Corresponding author
J. Sabo, Department of Medical and Clinical Biophysics, Faculty of Medicine, P. J. Šafárik University in Košice, Trieda SNP1, SK-04011 Košice, Slovakia. E-mail: jan.sabo@upjs.sk

Introduction
Endometrial cancer belongs to the one of the sixth most frequently occurred women’s malignant diseases around the world (i.e., 290 000 cases/year) (Amant et al. 2015). According to Bokman’s classification (Bokhman et al. 1983), there are two subtypes of such a disease, namely: endometrioid adenocarcinoma (Type I) and non-endometrioid carcinoma (Type II). The Type I carcinoma refers to almost 90% of all endometrial cancers. Regarding its characteristics, Type I is estrogens-dependent and there is a good prognosis for the early diagnosis. On the other hand, Type II is a highly aggressive, non-estrogens-dependent and unfortunately often diagnosed at higher degree of progression. The Type II tumors involve serous and clear-cell carcinomas as well as carcinosarcomas (Hussein and Soslow 2018, Mittal et al. 2016).

Nowadays, proteomics has taken a forefront attention in search of potential protein disease biomarkers. These unique substances can provide valuable information of ongoing/actual processes related to particular pathological pathways, performed on molecular level. To date, investigation of potential protein biomarkers of endometrial cancer has been focused mainly upon blood serum (Farias-Eisner et al. 2010, Takano et al. 2010) and/or tissues (Li et al. 2010,
Regarding other biological samples, urine provides several benefits over blood or solid biological samples (tissues), like non-invasive-based sampling in large quantities repeated as many times as necessary. However, so far, contributions to testing urine samples for searching of protein biomarkers of endometrial cancer have been poor.

In this work, we used urinary proteomics to monitor semi-quantitative changes of proteins in patients with endometrial cancer compared to control group. The basic pathophysiological role of potential protein biomarkers was evaluated.

**Methods**

**Biological material**

The research was approved by the Ethics Committee of the East Slovak Oncology Institute, Košice, Slovakia, and the Ethics Committee of the Medical Faculty, P. J. Šafárik University, Košice, Slovakia.

Five endometrial cancer patients (ECP) and seven healthy female individuals (control group), were included in the study. The first and second morning urine samples were taken from ECP, collected by spontaneous urination prior to surgery (performed at the Department of Gynaecology, East Slovak Oncology Institute, Košice, Slovakia). Table 1 provides all necessary characteristics of ECP. The control group included women feeling subjectively healthy. The Combur test (Roche Diagnostics) within the reference limits (specific weight, pH, leukocytes, nitrites, proteins, glucose, ketones, urobilinogen, bilirubin, blood), was used to monitor their analytes. In the time, i.e., when the samples were taken, the control group had not suffered any severe endometrial disease.

Table 1. Characterization of patients with endometrial cancer

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age</th>
<th>Histologic types</th>
<th>Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient 1</td>
<td>56</td>
<td>endometrioid adenocarcinoma</td>
<td>I.</td>
</tr>
<tr>
<td>Patient 2</td>
<td>51</td>
<td>endometrioid adenocarcinoma</td>
<td>II.</td>
</tr>
<tr>
<td>Patient 3</td>
<td>56</td>
<td>endometrioid adenocarcinoma</td>
<td>I.</td>
</tr>
<tr>
<td>Patient 4</td>
<td>56</td>
<td>endometrioid adenocarcinoma</td>
<td>I.</td>
</tr>
<tr>
<td>Patient 5</td>
<td>56</td>
<td>endometrioid adenocarcinoma</td>
<td>I.</td>
</tr>
</tbody>
</table>

**Experimental protocol**

Urine samples from both the ECP and control group were centrifuged at 12,000xg for 30 min at 4 °C (AVANTI J-301 centrifuge, Beckman Coulter). For further sample pretreatment, only supernatant was dialyzed overnight, against 3 mmol/dm³ glycine-HCl dialysis buffer (pH=3.2). After that, the dialyzed sample was preconcentrated on a CentriVap vacuum concentrator (Labconco). The preconcentrated sample was centrifuged at 30,000xg for 30 min at 4 °C (ALLEGRA 64R, Beckman Coulter). The obtained pellet was dissolved in a 50 mmol/dm³ Tris-HCl buffer (pH=8) and labelled as Fraction 1. The supernatant was preconcentrated once again to the desired volume, followed by ultracentrifugation at 802,000xg for 3 h at 4 °C using an OPTIMA L-100K ultracentrifuge (Beckman Coulter). At the end of the ultracentrifugation, the three next fractions were collected, as follows: the supernatant collected from the top of the tubes (SN1) was designated as Fraction 2, the supernatant obtained from the bottom of the tubes (SN2) was Fraction 3, and the pellet formed after ultracentrifugation was labelled as Fraction 4. After ultracentrifugation, the pellet was dissolved in 10 mmol/dm³ Tris-HCl buffer (pH=8). The supernatants (SN1 and SN2) were preconcentrated to the required volumes and dialyzed overnight, against 3 mmol/dm³ of Tris-HCl buffer (pH=8). The following day, each fraction was concentrated to a ~200 µl and analyzed.

**Measurement of total protein concentration**

The Bradford’s assay (Bradford 1976) was used to determine protein concentration in urine samples. The UV-3600 spectrophotometer (Shimadzu) was used to measure radiation absorption at 595 nm. Bovine serum albumin (BSA) standards were used to construct the calibration curve.

**In-solution digestion**

After measurement of total protein concentration, in-solution digestion was performed. To each fraction, the 200 mmol/dm³ dithiothreitol (DTT) in 50 mmol/dm³ Tris-HCl (pH=8) was added and incubated for 60 min at 57 °C. Subsequently, the 200 mmol/dm³ iodoacetamide (IAA) in 50 mmol/dm³ Tris-HCl (pH=8) was added to the fractions and incubated in the dark for 60 min at 25 °C. Again, the 200 mmol/dm³ DTT in 50 mmol/dm³ Tris-HCl (pH=8) was added to the fractions. The pH was adjusted to value of 8 using 2 mol/dm³ NH₄HCO₃. In the next step, trypsin was added.
in 1:10 (w/w) ratio and the fractions were incubated at 37 °C for 24 hrs. After protein digestion, the fractions were acidified to pH 4 with 20 % (v/v) formic acid. Ultimately, the samples were centrifuged on a microcentrifuge (MICROFUGE 22R, Beckman Coulter) at 14,000xg for 15 min at 4 °C.

**Nano HPLC-ESI-MS/MS analysis**

The fractions were analyzed as technical duplicates by nano HPLC (UltiMate 3000 RSLCnano, Thermo Scientific), which was coupled online with an ion trap electrospray mass spectrometer (amaZon speed ETD, Bruker Daltonik). In nano HPLC analysis, peptides were first preconcentrated on a trap column (Acclaim® PepMap 100 C18 trap column - 2 cm x 300 μm, particle size 5 μm, 100 Å, Thermo Scientific) and subsequently separated on an analytical column (Acclaim® PepMap RSLC - 15 cm x 75 μm, particle size 2 μm, 100 Å, Thermo Scientific) using mobile phase A (98 % water, 2 % acetonitrile containing 0.1 % formic acid) and mobile phase B (95 % acetonitrile, 5 % water containing 0.1 % formic acid). The following gradient elution was set: 4-35 % mobile phase B during 175 min; 35-95 % mobile phase B during 2 min; 95 % mobile phase B for 15 min and 95-4 % mobile phase B for 8 min. Subsequently, the column was equilibrated for 15 min at 4 % mobile phase B.

The following parameters for the mass spectrometry (MS) were set: enhanced mode, ion charge control (ICC) up to 400,000, maximum accumulation time up to 50 ms and mass scan range 300-1300 m/z. For MS/MS spectra, the following parameters were set: Xtreme resolution, ICC up to 500,000 and maximum accumulation time up to 100 ms.

**Statistical methods**

The Mascot 2.4 search engine (Matrix Science Ltd.) was used to identify proteins with the following taxonomy parameters: Human, database: SwissProt, fixed modification: carbamidomethylation of cysteine, variable modification: methionine oxidation, enzyme used to cleave proteins into peptides: trypsin, maximum number of cleavages omitted: 2, false discovery rate (FDR): less than 1 %.

Scaffold software (version 4.8.3, trial version) was applied for the semi-quantitative proteomic analysis without labelling (99 % probability of occurrence of a protein with at least 2 unique peptides identified; 95 % probability of peptide occurrence), using a quantification method normalized total spectra count and T-test (p≤0.05).

**Results**

As mentioned above, the acquired mass spectrometry data from ECP and control group were evaluated via Scaffold software. It has been shown that 181 proteins were identified with different regulations. Further, the label-free quantitative proteomic analysis

![Volcano plot (T-test, p < 0.05, No correction)](image)

**Fig. 1.** A volcano plot depicts 181 proteins (i.e., ECP/control proteins) with different regulation. The 76 proteins represent units with underwent significant changes (i.e., T-test, p≤0.05).
Fig. 2. Down-regulation of cadherin-1 in patients with endometrial cancer compared to the control group. The number I and II refer to the measurement of sample in technical duplicate.

Fig. 3. Down-regulation of vitronectin in endometrial cancer patients compared to control group. The number I and II refer to the measurement of sample in technical duplicate.

was performed based on the Normalised Total Spectral Count quantification method. The statistically significant changes (i.e., which pass T-test - \( p \leq 0.05 \)) were found in 76 proteins. The volcano plot displaying such outcome is depicted in Fig. 1.

Regarding proteins with significant changes, the basement membrane-specific heparan sulfate proteoglycan core protein (HSPG2), vitronectin (VTNC) and Cadherin-1 (CDH1) were further assessed in the manner of their log₂ up- and/or down-regulation (i.e., in ECP compared and control group) as these may play the significant role of being potential biomarkers of endometrial cancer. Here, Fig. 2-4 depict outcomes of normalised number of spectra of HSPG2, VTNC and CDH1, respectively. Results showed that there was a significant down-regulation of all studied proteins in
ECP when compared with healthy control group.

The calculated T-test, NTS, fold change and log₂FC data of studied HSPG2, VTNC and CDH1 are also provided in Table 2. To the note, a fold change (FC) was evaluated by comparing the NTS averages of the ECP and the control group. The results showed that the HSPG2 (log₂FC=-3.32) and CHDH-1 (log₂FC=-3.32) proteins represent the same decreases and ultimately VTN (log₂FC=-1.74 decrease).

Fig. 4. Down-regulation of basement membrane-specific heparan sulphate proteoglycan core protein specific for basement membrane in patients with endometrial cancer compared to control group. The number I and II refer to the measurement of sample in technical duplicate.

Table 2. Down-regulation of HSPG2, VTN and CDH1 proteins in ECP utilising the Normalised Total Spectra quantification method (T-test, p≤0.05)

<table>
<thead>
<tr>
<th>Proteins</th>
<th>Accession Number</th>
<th>MW* (kDa)</th>
<th>Control NTS* (average)</th>
<th>ECP* NTS* (average)</th>
<th>T-test (p≤0.05)</th>
<th>Fold Change</th>
<th>log₂ FC*</th>
</tr>
</thead>
<tbody>
<tr>
<td>HSPG2</td>
<td>PGBM_HUMAN</td>
<td>469</td>
<td>28.95</td>
<td>4.04</td>
<td>&lt; 0.00010</td>
<td>0.1</td>
<td>-3.32</td>
</tr>
<tr>
<td>VTN</td>
<td>VTNC_HUMAN</td>
<td>54</td>
<td>23.42</td>
<td>6.08</td>
<td>&lt; 0.00010</td>
<td>0.3</td>
<td>-1.74</td>
</tr>
<tr>
<td>CDH-1</td>
<td>CADH1_HUMAN</td>
<td>97</td>
<td>7.17</td>
<td>0.90</td>
<td>&lt; 0.00010</td>
<td>0.1</td>
<td>-3.32</td>
</tr>
</tbody>
</table>


Discussion

As mentioned above, the aim of the proposed study was differential urinary proteomics in endometrial cancer patients (ECP) and healthy control group. The changes in concentration of specific proteins between cancer patients and healthy controls have been previously observed in studies using invasive approach and searching for the potential biomarkers of endometrial cancer, breast cancer, ovarian cancer and cervical cancer in tissue and blood serum samples. Thus in this regard, we chose similar evaluation methodology. As indicated in results section, three proteins with significant differences in concentration were observed, namely cadherin-1, vitronectin and basement membrane-specific heparin sulphate proteoglycan core protein. Cadherin-1 (E-cadherin) is a calcium-dependent transmembrane glycoprotein, relevant in establishing adherent
connections between epithelial cells. It is linked to cytoskeletal actin filaments via α- and β- (or possibly γ-) catenin (Schlosshauer et al. 2002, Xiong et al. 2016). Its role in inhibiting invasion and metastasis is related to prevention of triggering (first step) of the metastatic cascade (Mell et al. 2004). Several studies have shown that decreased concentrations of E-cadherin have facilitated tumor invasion and metastasis in breast cancer (Yoshida et al. 2001), ovarian cancer (Veatch et al. 1994), endometrial cancer (Yalta et al. 2009), and others. Also, elsewhere (Koyuncuoglu et al. 2012), it has been observed, that decreased E-cadherin concentration correlates with adverse prognostic factors in both types (I, II) of endometrial cancers.

Similarly as in E-cadherin, vitronectin protein exhibited lower concentration in endothelial cancer patients (ECP) than in control group as seen in Figure 3. Vitronectin is a main plasma glycoprotein with multiple functions including regulation of cell differentiation, proliferation and morphogenesis (cell adhesion molecule) (Turan et al. 2017). It also belongs among the major components of the extracellular matrix together with collagens, laminin and fibronectin. The tumor microenvironment is an important factor contributing to the promotion of tumorigenesis (Mu et al. 2012). It has been pointed out that vitronectin plays an important role in pathophysiological processes and its biosynthesis can be regulated during disease progression. By using ELISA approach, a significant decrease of vitronectin in serum of patients with endometrial and ovarian cancer was observed (Turan et al. 2017). Similar reduced concentration in breast cancer samples was figured out, elsewhere (Kim et al. 2009). Controversially, elevated concentration of vitronectin in patients’ serum having ductal breast cancer tested in situ was an outcome as reported by Kadowaki et al. (2011).

Regarding basement membrane-specific heparan sulphate proteoglycan core protein (perlecan) specific for the basement membrane, it is a large protein highly represented in the extracellular matrix and basement membranes of normal tissues and blood vessels (Davies et al. 2004). The perlecan deficiency may promote the diffusion of heparin-binding growth factors, leading to increased tumor growth. Its function in tumor invasion and metastasis depends on the character of the cell. Perlecan may also promote tumor angiogenesis (Jiang et al. 2003). Our results (Fig. 4), indicates reduced concentration of perlekan in EPC compared to control group, what is in agreement with results of Shinyo et al. (Shinyo et al. 2005), who reported that loss of HSPG2 expression may serve as an indicator of aggressive disease potential. Similarly, Hasengaowa et al. (2005) found out that decreased HSPG2 concentration in the basement membrane is associated with tumor progression but is not a sufficient prognostic factor in patients with endometrial cancer.

According to our results, urinary proteomics is a promising tool in the search for potential endometrial cancer biomarkers as it may serve as the approach for clinical early non-invasive diagnostics. The easy-to-collect feature and the possibility of sampling of large volumes of urine sample represent a major advantage over the other biological samples like tissue, plasma, serum and/or cerebrospinal fluid. Therefore, authors believe that urine has a potential to be a sample of choice for diagnostics in future when treating cancer patients’ samples.

Conflict of Interest
There is no conflict of interest.

Acknowledgements
The authors would like to acknowledge for the financial support of the research The Research Agency of the Ministry of Education, Science, Research and Sport of the Slovak Republic under projects ITMS: 26220120039, the project PON-MIUR, project No. LO1605 the Internal Grant Agency of the Ministry of Health of the Czech Republic 16-29680A and 17-32285A, GAUK 512216 and BIONECA COST action CA1622.

References


HUSSEIN YR, SOSLOW RA: Molecular insights into the classification of high-grade endometrial carcinoma. *Pathology* **50**: 151-161, 2018.


